MarketPeel
Insider Trading Intelligence
Pricing
…
JK

Jeff E. Knight

CRNX
CHIEF OPERATING OFFICER · CRINETICS PHARMACEUTICALS, INC. · CIK 0001881007
FILING MIX · LIFETIME50%/50%
BUYS
20
SELLS
20
TOTAL VALUE
$10.30M
COMPANIES
2
ACTIVE SINCE
Sep 2021
HOLDINGS NOW
990,452
AVG SELL PX
$42.69
TRADE KIND
SHOWING 40 / 40
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
11 backtested trades · 8 horizons · 14 pending
Forward-return performance of every backtestable P/S trade by Jeff E. Knight, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d11+63.64%-0.46%+0.61%-1.07%-1.02%—
14d11+45.45%+0.57%-0.00%+0.57%-2.02%—
30d11+63.64%+0.22%+0.04%+0.18%-1.84%—
60d11+54.55%-2.95%+4.03%-6.97%-10.78%—
90d11(1 pending)+90.00%-7.61%+5.26%-12.87%-15.67%—
180d11(3 pending)+62.50%-1.72%+8.19%-9.91%-13.02%—
1y11(3 pending)+75.00%-17.48%+13.43%-30.91%-31.87%—
2y11(7 pending)+75.00%+25.33%+32.81%-7.48%-48.97%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
CRNX · 190,452 shares · as of Apr 8, 2026
047,61395,226142,839190,45220222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 20 buys / 20 sellsCOVERAGE · 20 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
ALXO
ALX ONCOLOGY HOLDINGS INC
PURCHASEGRANT
Stock grant
800,000——800,000Apr 16, 2026Apr 17, 2026 ↗View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
SALE
Chief Dev. & Operating Officer
49,474——63,027Apr 8, 2026Apr 10, 2026 ↗View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
85,163$40.10$3.42M105,289Apr 8, 2026Apr 10, 2026 ↗View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
PURCHASE
Chief Dev. & Operating Officer
9,624$20.02$192.7K171,116Apr 8, 2026Apr 10, 2026 ↗View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
PURCHASE
Chief Dev. & Operating Officer
49,474$23.98$1.19M161,492Apr 8, 2026Apr 10, 2026 ↗View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
SALE
Chief Dev. & Operating Officer
19,336——65,977Apr 8, 2026Apr 10, 2026 ↗View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
SALE
Chief Dev. & Operating Officer
9,624——10,589Apr 8, 2026Apr 10, 2026 ↗View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
PURCHASE
Chief Dev. & Operating Officer
19,336$19.64$379.8K190,452Apr 8, 2026Apr 10, 2026 ↗View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
3,961$37.77$149.6K112,018Mar 16, 2026Mar 18, 2026 ↗View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
5,950$37.11$220.8K115,979Mar 16, 2026Mar 18, 2026 ↗View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
55,000——55,000Feb 23, 2026Feb 25, 2026 ↗View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
34,000——121,929Feb 23, 2026Feb 25, 2026 ↗View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
6,801$34.17$232.4K87,852Mar 19, 2025Mar 21, 2025 ↗View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
361$34.83$12.6K87,491Mar 19, 2025Mar 21, 2025 ↗View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
43,000——94,653Feb 20, 2025Feb 24, 2025 ↗View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
65,000——65,000Feb 20, 2025Feb 24, 2025 ↗View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
501$56.52$28.3K51,653Nov 22, 2024Nov 26, 2024 ↗View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
PURCHASE
Chief Operating Officer
2,887$20.02$57.8K72,966Jul 15, 2024Jul 17, 2024 ↗View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
SALE
Chief Operating Officer
17,499——112,501Jul 15, 2024Jul 17, 2024 ↗View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
PURCHASE
Chief Operating Officer
17,499$23.98$419.6K70,079Jul 15, 2024Jul 17, 2024 ↗View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
SALE
Chief Operating Officer
5,687——85,313Jul 15, 2024Jul 17, 2024 ↗View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
PURCHASE
Chief Operating Officer
5,687$19.64$111.7K78,653Jul 15, 2024Jul 17, 2024 ↗View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
27,000$55.00$1.49M51,653Jul 15, 2024Jul 17, 2024 ↗View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
SALE
Chief Operating Officer
2,887——20,213Jul 15, 2024Jul 17, 2024 ↗View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
956$44.38$42.4K52,580Jun 26, 2024Jun 28, 2024 ↗View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
SALE
Chief Operating Officer
30,000$44.22$1.33M54,939Mar 22, 2024Mar 26, 2024 ↗View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
SALE
Chief Operating Officer
2,359$45.39$107.1K52,580Mar 22, 2024Mar 26, 2024 ↗View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
PURCHASE
Chief Operating Officer
30,000$23.98$719.4K84,939Mar 22, 2024Mar 26, 2024 ↗View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
SALE
Chief Operating Officer
30,000——130,000Mar 22, 2024Mar 26, 2024 ↗View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
SALE
Chief Operating Officer
4,283$38.14$163.4K54,939Mar 18, 2024Mar 20, 2024 ↗View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
87,000——87,000Mar 4, 2024Mar 6, 2024 ↗View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
23,000——59,222Mar 4, 2024Mar 6, 2024 ↗View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
SALE
Chief Operating Officer
587$17.12$10.0K34,400Mar 16, 2023Mar 17, 2023 ↗View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
91,000——91,000Mar 1, 2023Mar 3, 2023 ↗View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
29,500——34,987Mar 1, 2023Mar 3, 2023 ↗View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
SALE
Chief Operating Officer
1,152$20.70$23.8K4,950Jul 26, 2022Jul 29, 2022 ↗View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
PURCHASE
Chief Operating Officer
1,152$17.44$20.1K6,102May 20, 2022Jul 29, 2022 ↗View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
4,950——4,950Feb 28, 2022Mar 2, 2022 ↗View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
23,100——23,100Feb 28, 2022Mar 2, 2022 ↗View →
CRNX
CRINETICS PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
160,000——160,000Sep 1, 2021Sep 2, 2021 ↗View →
Other insiders · CRNX
Loading peer insiders…
About this filer
CIK 0001881007
ROLE
Chief Operating Officer
PRIMARY
CRNX
COMPANIES
2
ACTIVE SINCE
Sep 2021
MARKETPEEL · /INSIDER/0001881007DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback